A family-run pharmaceutical house working across three lines: export trading of trusted brands, our own manufactured formulations, and care coordination for patients travelling to India for treatment.
Towada exports across five core therapeutic categories, supplying distributors and institutions in Southeast Asia, the CIS region, the Middle East, and parts of Europe and Africa.
Every shipment is backed by a documented compliance stack, from manufacturing license to foreign exchange reporting.
We ship via trusted international courier and air cargo partners, chosen based on destination, shipment size, and urgency — with tracked, documented dispatch on every order.
Small and time-sensitive consignments typically move via DHL, FedEx, UPS, or EMS with door-to-door tracking; larger volume orders are routed through air cargo. Every shipment is packed and documented to meet destination-country import requirements.
A snapshot of our catalog — sourced from our verified IndiaMART storefront, 12 years and 4.6★ (346 reviews) strong. Full pricing, packaging, and specification sheets are available on request.
Prices shown in USD for international buyers, indicative only — contact us for a formal quote.
This is a curated preview of our featured range. Browse the complete catalog of 653 products across oncology, HIV, hepatitis, transplant, cardiac, and general therapeutics.
Beyond trading established brands, Towada is developing its own manufactured product line — starting in oncology, with plans to register future formulations across multiple export markets.
Manufactured under contract to Towada's specification and quality requirements, marking the first product in our own-brand portfolio. To be sold by retail only on the prescription of a Registered Oncologist.
Formulations are produced by qualified third-party manufacturers to Towada's specifications.
Each batch is checked against required quality and regulatory standards before release.
Products are progressively registered across our target export geographies.
Enzalutamide is the first of a growing own-brand range planned across our core therapeutic areas.
Through relationships with hospitals across New Delhi, Towada helps international patients and their families find the right specialists and navigate treatment in India — from first enquiry to hospital admission.
Connecting patients with the right hospital and specialist for their condition, from our network across New Delhi.
Helping arrange appointments, second opinions, and documentation ahead of arrival.
Guidance on travel planning, accommodation, and getting settled during the treatment period.
A point of contact in Delhi throughout the visit, for questions and day-to-day assistance.
Towada facilitates access to independent hospitals and specialists; treatment decisions rest entirely with the treating hospital and physician. If you're exploring treatment in India for yourself or a family member, reach out and we'll help you understand the right next step.
Towada Products is run out of Naraina Industrial Area, New Delhi, as a family partnership — built on the belief that reliable medicine supply, honest manufacturing, and genuine patient support can sit under one roof.
Operating out of Naraina Industrial Area, New Delhi, with export relationships spanning Southeast Asia, the CIS region, the Middle East, and parts of Europe and Africa — alongside a growing own-brand manufacturing pipeline and hospital network in Delhi.
Feedback from importers, distributors, and patients we've worked with — shared publicly on our Google Business profile.
Praised the team's professionalism and patience in walking a first-time customer through the ordering and payment process for their medication.
A repeat customer noted attentive, engaging representatives and safe delivery of medicines at fair prices, while suggesting further improvement on delivery timelines.
Thanked Harmeet Singh Gandhi personally for prompt follow-up on a shipment issue, with the missing item dispatched quickly once flagged.
Called out Towada's professional service, fast delivery, and product knowledge, crediting Harmeet with making the import of a critical medicine a smooth experience.
Described the service as highly responsible and conducted with great manners, expressing full trust in the team.
We track regulatory approvals and market developments across Hepatitis B/C, HIV, Oncology, and Erectile Dysfunction — the categories we export in — so our partners stay informed.
Gilead's Bixlenvo combines bictegravir 75mg and lenacapavir 50mg into the smallest once-daily single-tablet regimen for virologically suppressed HIV patients, offering the first single-tablet option for patients unable to take currently available regimens. A meaningful new option for treatment-experienced HIV patients.
Approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy — a RAS GTPase inhibitor addressing a historically hard-to-treat cancer.
Approved in combination with chemotherapy and tislelizumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Expands first-line options in HER2+ GI cancers.
